6 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 6 |
| Phase 2 | 3 | Unknown 3 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Tolerability Study of Jaktinib Jaktinib Hydrochloride Tablet - Myelofibrosis | Phase 1 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 26 | 2024-07-01 | 2024-03-21 |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies EP31670 - Castrate Resistant Prostate Cancer, NUT Carcinoma | Phase 1 | Unknown | Epigenetix, Inc. | 75 | 2022-12-21 | 2025-01-14 |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis TBX-2400 - Myelofibrosis, Acute Myelogenous Leukemia | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 10 | 2022-09-01 | 2022-05-03 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib KRT-232, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 36 | 2021-01-28 | 2022-05-09 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF KRT-232, TL-895 - Myelofibrosis, Post-PV MF | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 116 | 2020-11-17 | 2022-05-09 |
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
Primary Myelofibrosis (6) · Bone Marrow Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Myeloproliferative Disorders (5) · Neoplasms (3) · Hematologic Neoplasms (2) · Leukemia, Myeloid (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Neoplasms (1) · Chronic Disease (1) · Disease Attributes (1) · Hemorrhagic Disorders (1)
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2) · NEO2734 (1) · lestaurtinib (1) · ruxolitinib (1)
Kartos Therapeutics, Inc. (2) · Epigenetix, Inc. (1) · Ronald Hoffman (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Taiga Biotechnologies, Inc. (1)
United States (5) · Italy (3) · Bulgaria (2) · France (2) · Germany (2) · Poland (2) · Spain (2) · Australia (1) · Austria (1) · Croatia (1) · Hungary (1) · Israel (1) · Serbia (1)
Andrea Bacigalupo, MD (1) · Judy Chiao, MD (1) · Ronald Hoffman, MD (1)
P01CA108671 (1)